Pacific Biosciences of CaliforniaPACB +11.11%53 Median PS Value is $3.96 as of Jun. 26, 2026, which is 236% above its 10-year median of 1.18. GuruFocus rates PACB with a GF Score™ of 53/100 and a GF Value™ of $1.62 (Fairly Valued). The stock has 8 warning signs investors should review. Among 338 Medical Devices & Instruments companies, Pacific Biosciences of California ranks better than 78.99% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Pacific Biosciences of California's Median PS Value or its related term are showing as below:
PACB'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.22 Med: 1.18 Max: 9.33
Current: 0.4
During the past 13 years, the highest Price to Median PS Value of Pacific Biosciences of California was 9.33. The lowest was 0.22. And the median was 1.18.
PACB's Price-to-Median-PS-Value is ranked better than 78.99% of 338
companies
in the Medical Devices & Instruments industry
Industry Median: 0.71
vs PACB: 0.40
Pacific Biosciences of California (NAS:PACB) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Pacific Biosciences of California's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
1.60
/
3.96
=
0.40
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Biosciences of California Median PS Value Related Terms
Pacific Biosciences of California Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Biosciences of California Median PS Value Chart
PACB vs CATX, LAB, KIDS: Median PS Value Comparison
For the Medical Devices subindustry, Pacific Biosciences of California's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacific Biosciences of California Price-to-Median-PS-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Pacific Biosciences of California's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 7.4717.
Pacific Biosciences of California's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.53.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Biosciences of California (PACB) has a Median PS Value of $3.96 as of Jun. 26, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Pacific Biosciences of California and its competitors. This is 236% above median its historical median of 1.18. Over the past decade, Pacific Biosciences of California's Median PS Value has ranged from 0.22 to 9.33. According to the industry distribution chart, Pacific Biosciences of California ranks #71 out of 338 companies in the Medical Devices & Instruments industry, placing it in the top 21%.
Is Pacific Biosciences of California's Median PS Value too high?
Pacific Biosciences of California's current Median PS Value of $3.96 is 236% above median its 10-year median of 1.18. Over the past 10 years, this metric has ranged from a low of 0.22 to a high of 9.33. The Medical Devices & Instruments industry median Median PS Value is 0.71. Pacific Biosciences of California's value of $3.96 is 457.7% above this industry median. Based on the distribution chart, Pacific Biosciences of California ranks #71 out of 338 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Pacific Biosciences of California has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's Median PS Value compare to CATX and LAB?
According to the Medical Devices & Instruments industry distribution chart, Pacific Biosciences of California ranks #71 out of 338 companies for Median PS Value. This places Pacific Biosciences of California in the top 21% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.71. Pacific Biosciences of California's value of $3.96 is 457.7% above this benchmark. Historically, Pacific Biosciences of California's own Median PS Value has ranged from 0.22 to 9.33 over the past decade. While the company's 10-year median is 1.18 vs. the industry median of 0.71, Pacific Biosciences of California has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Devices & Instruments company?
The median Median PS Value among Medical Devices & Instruments companies is 0.71, based on 338 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacific Biosciences of California's current Median PS Value of $3.96 is 457.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Pacific Biosciences of California and its competitors. For the Medical Devices & Instruments industry, the median Median PS Value is 0.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacific Biosciences of California's current Median PS Value is $3.96, which is 236% above median its own 10-year median of 1.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Based on GuruFocus' analysis, Pacific Biosciences of California (PACB) is currently considered Fairly Valued. The stock's GF Value™ is $1.62, compared to a current price of $1.60 — trading 1.2% below its estimated fair value. The current Median PS Value is $3.96, which is 236% above median its 10-year median of 1.18 and 457.7% above the Medical Devices & Instruments industry median of 0.71. Pacific Biosciences of California's overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Pacific Biosciences of California (PACB), the current Median PS Value is $3.96 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacific Biosciences of California (PACB) Overvalued in 2026?
Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be undervalued.
The current stock price of $1.60 is trading 1.2% below its estimated GF Value™ of $1.62.
GuruFocus considers Pacific Biosciences of California to be Fairly Valued.
Key valuation signals for PACB:
Median PS Value: $3.96 (236% above median its 10-year median of 1.18)
GF Value™: $1.62 vs. price of $1.60 (1.2% below fair value)
Industry Position: 457.7% above the Medical Devices & Instruments median (#71 of 338)
No single metric tells the full story. See the PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacific Biosciences of California Business Description
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
53GF Score
Get the complete analysis for PACB
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PACB has been successfully added to your 
